328 related articles for article (PubMed ID: 34549909)
1. Chimeric Antigen Receptor T-Cell Therapeutics for Multiple Myeloma: Moving Into the Spotlight.
Wang B; Rajeeve S; Madduri D
Cancer J; 2021 May-Jun 01; 27(3):205-212. PubMed ID: 34549909
[TBL] [Abstract][Full Text] [Related]
2. Multiple Myeloma, Targeting B-Cell Maturation Antigen With Chimeric Antigen Receptor T-Cells.
Shah UA; Smith EL
Cancer J; 2019; 25(3):208-216. PubMed ID: 31135528
[TBL] [Abstract][Full Text] [Related]
3. European Myeloma Network perspective on CAR T-Cell therapies for multiple myeloma.
Bruno B; Wäsch R; Engelhardt M; Gay F; Giaccone L; D'Agostino M; Rodríguez-Lobato LG; Danhof S; Gagelmann N; Kröger N; Popat R; Van de Donk NWCJ; Terpos E; Dimopoulos MA; Sonneveld P; Einsele H; Boccadoro M
Haematologica; 2021 Aug; 106(8):2054-2065. PubMed ID: 33792221
[TBL] [Abstract][Full Text] [Related]
4. BCMA-targeting chimeric antigen receptor T-cell therapy for multiple myeloma.
Yang J; Zhou W; Li D; Niu T; Wang W
Cancer Lett; 2023 Jan; 553():215949. PubMed ID: 36216149
[TBL] [Abstract][Full Text] [Related]
5. CAR T-cell therapy against B-cell maturation antigen in multiple myeloma.
Cohen AD
Clin Adv Hematol Oncol; 2018 Dec; 16(12):804-806. PubMed ID: 30843888
[No Abstract] [Full Text] [Related]
6. BCMA-targeted CAR-T cell therapies in relapsed and/or refractory multiple myeloma: latest updates from 2023 ASCO Annual Meeting.
Wu JF; Dhakal B
J Hematol Oncol; 2023 Jul; 16(1):86. PubMed ID: 37507805
[TBL] [Abstract][Full Text] [Related]
7. T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma.
Brudno JN; Maric I; Hartman SD; Rose JJ; Wang M; Lam N; Stetler-Stevenson M; Salem D; Yuan C; Pavletic S; Kanakry JA; Ali SA; Mikkilineni L; Feldman SA; Stroncek DF; Hansen BG; Lawrence J; Patel R; Hakim F; Gress RE; Kochenderfer JN
J Clin Oncol; 2018 Aug; 36(22):2267-2280. PubMed ID: 29812997
[TBL] [Abstract][Full Text] [Related]
8. Multiple Myeloma: The CAR T-cell Therapy Landscape.
Cancer Discov; 2020 Feb; 10(2):OF6. PubMed ID: 31915196
[TBL] [Abstract][Full Text] [Related]
9. CAR T cell therapy for multiple myeloma: where are we now and where are we headed?
Ghosh A; Mailankody S; Giralt SA; Landgren CO; Smith EL; Brentjens RJ
Leuk Lymphoma; 2018 Sep; 59(9):2056-2067. PubMed ID: 29105517
[TBL] [Abstract][Full Text] [Related]
10. Chimeric Antigen Receptor T Cells in the Treatment of Multiple Myeloma.
Hasanali ZS; Razzo B; Susanibar-Adaniya SP; Garfall AL; Stadtmauer EA; Cohen AD
Hematol Oncol Clin North Am; 2024 Apr; 38(2):383-406. PubMed ID: 38158242
[TBL] [Abstract][Full Text] [Related]
11. Chimeric Antigen Receptor T Cells in Multiple Myeloma.
Shah P; Sperling AS
Hematol Oncol Clin North Am; 2023 Dec; 37(6):1089-1105. PubMed ID: 37563077
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of CAR-T Therapy for Relapse or Refractory Multiple Myeloma: A systematic review and meta-analysis.
Yang Q; Li X; Zhang F; Yang Q; Zhou W; Liu J
Int J Med Sci; 2021; 18(8):1786-1797. PubMed ID: 33746596
[No Abstract] [Full Text] [Related]
13. Current advances in chimeric antigen receptor T-cell therapy for refractory/relapsed multiple myeloma.
Huang H; Wu HW; Hu YX
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):29-41. PubMed ID: 31898440
[TBL] [Abstract][Full Text] [Related]
14. Chimeric antigen receptor (CAR) T-cell therapy for multiple myeloma.
Choi T; Kang Y
Pharmacol Ther; 2022 Apr; 232():108007. PubMed ID: 34582835
[TBL] [Abstract][Full Text] [Related]
15. Perspectives for the Use of CAR-T Cells for the Treatment of Multiple Myeloma.
Jasiński M; Basak GW; Jedrzejczak WW
Front Immunol; 2021; 12():632937. PubMed ID: 33717171
[TBL] [Abstract][Full Text] [Related]
16. Clinical experience of CAR T cells for multiple myeloma.
Simmons GL; Satta T; Castaneda Puglianini O
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101306. PubMed ID: 34625232
[TBL] [Abstract][Full Text] [Related]
17. Overview of anti-BCMA CAR-T immunotherapy for multiple myeloma and relapsed/refractory multiple myeloma.
Feng D; Sun J
Scand J Immunol; 2020 Aug; 92(2):e12910. PubMed ID: 32471019
[TBL] [Abstract][Full Text] [Related]
18. Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.
Chen D; Wang X; Chen Z; Jiang S; Jiang H; Fu W; Xiang F; Sun X; Du J
Am J Hematol; 2022 Dec; 97(12):E478-E481. PubMed ID: 36197023
[No Abstract] [Full Text] [Related]
19. Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.
Marofi F; Tahmasebi S; Rahman HS; Kaigorodov D; Markov A; Yumashev AV; Shomali N; Chartrand MS; Pathak Y; Mohammed RN; Jarahian M; Motavalli R; Motavalli Khiavi F
Stem Cell Res Ther; 2021 Mar; 12(1):217. PubMed ID: 33781320
[TBL] [Abstract][Full Text] [Related]
20. Impact of high-risk disease on the efficacy of chimeric antigen receptor T-cell therapy for multiple myeloma: a meta-analysis of 723 patients.
Gagelmann N; Ayuk FA; Klyuchnikov E; Wolschke C; Berger SC; Kröger N
Haematologica; 2023 Oct; 108(10):2799-2802. PubMed ID: 36815380
[No Abstract] [Full Text] [Related]
[Next] [New Search]